Sortera Bio Announces Strategic Collaboration with AstraZeneca to Accelerate Novel Biologics Discovery and Development
Cambridge, UK – 30th July 2025 – Sortera Bio Ltd, a pioneering biotechnology company, today announced a strategic collaboration with AstraZeneca, a global science-led biopharmaceutical company. This collaboration will leverage Sortera Bio’s innovative Deep Screening platform to identify early drug hits to potential drug targets and accelerate the discovery and development of novel biologics.
The collaboration builds on the existing relationship between Sortera Bio and AstraZeneca, which began through the Medical Research Council Laboratory of Molecular Biology (MRC LMB)-AstraZeneca Blue Sky Collaboration, where Sortera’s technology was initially developed. Under this new agreement, AstraZeneca will continue to access Sortera Bio’s proprietary Deep Screening platform, which enables the precise identification of potential therapeutic candidates with desirable drug-like properties by experimentally collecting sequence and functional data for hundreds of millions of biologics in a single experiment.
“We are thrilled to expand our collaboration with AstraZeneca, further building on the successful LMB-AstraZeneca Blue Sky initiative that helped develop our foundational technology,” said Ben Porebski, PhD, CEO-CTO of Sortera Bio. “This collaboration represents a significant milestone in our mission to redefine early biologics discovery and engineering. By combining our Deep Screening capabilities with AstraZeneca’s expertise in AI assisted biologics discovery, we aim to rapidly discover precision biologics that have the potential to benefit patients.”
The collaboration will enable both companies to utilise their complementary strengths to drive innovation in biologics discovery. AstraZeneca’s extensive capabilities in drug discovery and development will help to realise the potential of Sortera Bio’s innovative Deep Screening platform and support its application, with the potential to address some of the most pressing challenges in healthcare.
ENDS
About Sortera Bio
Sortera Bio Ltd is a Cambridge UK-based biotechnology company based on intellectual property developed at the MRC Laboratory of Molecular Biology. Sortera is focused on accelerating the discovery of biologics via its proprietary Deep Screening platform and is dedicated to delivering transformative solutions in biologics discovery to meet the needs of patients worldwide.
Contact: hello@sortera.bio
https://sortera.bio
Follow Sortera Bio on LinkedIn